

## **MTG Accelerated Access Review – MTG Consultation Response**

### **The MTG**

The Medical Technology Group (MTG) is a coalition of patient groups, research charities and medical device manufacturers working to make medical technologies available for everyone who needs one.

### **Key Points for the AAR**

- Encourage patient and public input via proper stakeholder engagement including NHS England consultations, Monitor decisions and ensuring patient representation on decision making boards. These consultations should also be properly advertised and decisions should be signposted. Consultations should give adequate time for input from patient organisations and wider stakeholders.
- It is important to ensure that proven innovative technology is taken up across the NHS. This includes technology with NICE guidance as well as NICE Technology Appraisals. At the same time it is important that patients have access to proven innovative technology, not just those with a TA which go through a lengthy and expensive approval process.
- In the NHS it is important to distinguish the differences between the evidence base and data of pharmaceuticals and medical technology. This is essential to ensure patient access to innovative medical technology. Indeed different evaluation methodology and criteria are needed for Medical Technology and this should be proportionate and not overly burdensome.
- It is key to ensure Tariff, and other incentives, encourage the use of innovative medical technology rather than referring to the cheapest option, which is often not the most cost effective or clinically effective option for patients. It is important to put the patient first when making decisions about which treatment option to take.
- Underlying costs used to reimburse hospitals for patient treatments must be accurate and adequate to maintain sustainable services for patients to access – something which seems improbable given the significant volatility observed in tariffs from one year to the next.
- Commissioners and providers of healthcare must be enabled to make sound long term treatment decisions which offer value to patients and the NHS over many years not just the lowest cost today. It is a considerable frustration that the overall measures for financial performance are so short term relating to buying things cheaper today rather than reducing the total cost across a patient pathway which may span many years.
- We fear for the future of a system where hospitals are being driven into large deficits because their funding is being cut every year through tariff. This will disadvantage patients needing more specialised treatments disproportionately which is inequitable and in the worst interests of patients
- Transparency around decision making, and treatment options, is essential throughout the NHS including those made by NHS England which have become rather opaque. Patients must be able to easily understand their options and what decisions are being made.
- Patient education and awareness is key. This can be encouraged through patient groups and meaningful stakeholder engagement.
- Best practice examples of uptake of medical innovation that have been successful, as highlighted in the MTG case study document, are examples to work from across the country.

ABHI, AdvaMed, AntiCoagulation Europe, ARMA, Arrhythmia Alliance, Arthritis Care, Atrial Fibrillation Association, BD, BKPA, Bladder and Bowel Foundation, Boston Scientific, British Cardiac Patients Association, C R Bard, Cardiomyopathy Association, Diabetes UK, Eucomed, FABLE, FEmISA, Heart Research UK, ICD Group, INPUT, Insightec, International Alliance of Patients' Organizations, JDRC, Johnson & Johnson, Lindsay Leg Club, Medtronic, National Rheumatoid Arthritis Society, Pancreatic Cancer UK, Pelvic Pain Support Network, Pumping Marvellous, Roche Diagnostics, SADS UK, Smith & Nephew, Smiths Medical, St Jude Medical, STARS, Stryker, The Circulation Foundation, The Patients Association



- Above all the patient must be put first when making decisions and when consulting about decisions within the NHS.
- The MTG hopes that the AAR learns from the attempted implementation of recommendations from IHW in order to make the AAR successful across the country, please see attached report published by the MTG.
- The MTG welcomes the AAR and opportunities to feed into this report and this opportunity to encourage uptake of proven innovative medical technology.